DK2338487T3 - Kombinationsterapi med PARP-inhibitorer - Google Patents

Kombinationsterapi med PARP-inhibitorer

Info

Publication number
DK2338487T3
DK2338487T3 DK11157696.3T DK11157696T DK2338487T3 DK 2338487 T3 DK2338487 T3 DK 2338487T3 DK 11157696 T DK11157696 T DK 11157696T DK 2338487 T3 DK2338487 T3 DK 2338487T3
Authority
DK
Denmark
Prior art keywords
parp inhibitors
combination therapy
combination
formula
inhibitors
Prior art date
Application number
DK11157696.3T
Other languages
English (en)
Inventor
Wolfgang Wernet
Thomas D Penning
Vincent L Giranda
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Application granted granted Critical
Publication of DK2338487T3 publication Critical patent/DK2338487T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK11157696.3T 2006-01-17 2007-01-17 Kombinationsterapi med PARP-inhibitorer DK2338487T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US75944506P 2006-01-17 2006-01-17
US80411206P 2006-06-07 2006-06-07
US85004206P 2006-10-06 2006-10-06
US82926106P 2006-10-12 2006-10-12
US86751806P 2006-11-28 2006-11-28
EP07716699A EP1976515A2 (en) 2006-01-17 2007-01-17 Combination therapy with parp inhibitors

Publications (1)

Publication Number Publication Date
DK2338487T3 true DK2338487T3 (da) 2013-12-09

Family

ID=38141258

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11157696.3T DK2338487T3 (da) 2006-01-17 2007-01-17 Kombinationsterapi med PARP-inhibitorer

Country Status (14)

Country Link
US (4) US20070265324A1 (da)
EP (3) EP2329818A1 (da)
JP (4) JP5289060B2 (da)
CN (1) CN101370497B (da)
CA (1) CA2635691C (da)
DK (1) DK2338487T3 (da)
ES (1) ES2437132T3 (da)
HR (1) HRP20131180T1 (da)
ME (1) ME02121B (da)
PL (1) PL2338487T3 (da)
PT (1) PT2338487E (da)
RS (1) RS53082B (da)
SI (1) SI2338487T1 (da)
WO (1) WO2007084532A2 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL347500A1 (en) 1998-11-03 2002-04-08 Basf Ag Substituted 2-phenylbenzimidazoles, the production thereof and their use
WO2006110683A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
CA2612979A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. Parp modulators and treatment of cancer
ZA200800907B (en) 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
CA2623822C (en) * 2005-09-29 2013-11-12 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
CN101309908A (zh) * 2005-11-15 2008-11-19 艾博特公司 作为有效parp抑制剂的取代的1h-苯并咪唑-4-甲酰胺化合物
MX2008014004A (es) * 2006-05-02 2008-11-12 Abbott Lab 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
CN101534836B (zh) 2006-09-05 2011-09-28 彼帕科学公司 Parp抑制剂在制备治疗肥胖症的药物中的用途
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
CN103169973A (zh) 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
MX2010008572A (es) * 2008-02-04 2010-11-30 Bipar Sciences Inc Metodos de diagnostico y tratamiento de enfermedades mediadas por poli(adp-ribosa) polimerasa.
WO2012016876A1 (en) * 2010-08-03 2012-02-09 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising a parp-1 inhibitor and an anti-neoplastic agent
TWI386203B (zh) * 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
JP2014510787A (ja) 2011-04-11 2014-05-01 アッヴィ・インコーポレイテッド Ｃｉｐｎの治療のためのｐａｒｐ阻害剤
EP2849750A1 (en) 2012-05-15 2015-03-25 AbbVie Inc. Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
CN104230896A (zh) * 2013-06-17 2014-12-24 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
SG11201604658XA (en) 2013-12-10 2016-07-28 Abbvie Inc Veliparib in combination with carboplatin for the treatment of triple negative breast cancer
MX2016009167A (es) * 2014-01-14 2016-09-09 Nektar Therapeutics Metodo de tratamiento basado en combinacion.
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
JP7042739B2 (ja) 2015-08-20 2022-03-28 イプセン バイオファーム リミティド 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
TW202243677A (zh) 2015-08-21 2022-11-16 英商益普生生物製藥有限公司 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
CN105712937B (zh) * 2016-02-28 2019-02-22 河北宁格生物医药科技有限公司 一种治疗转移性肿瘤的化合物及其用途
MX2019004783A (es) 2016-11-02 2019-08-12 Ipsen Biopharm Ltd Tratamiento de cancer gastrico usando terapias de combinacion que comprenden irinotecan liposomico oxaliplatino, 5-fluoruracilo (y leucovorina).
GB201709076D0 (en) * 2017-06-07 2017-07-19 Inst Of Cancer Research: Royal Cancer Hospital Parp inhibitors for use in methods of treating cancer
WO2019136298A1 (en) 2018-01-05 2019-07-11 Cybrexa, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
CN111936143A (zh) 2018-04-05 2020-11-13 诺维嘉研究公司 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品
CN109232540A (zh) * 2018-06-15 2019-01-18 深圳市坤健创新药物研究院 一种取代苯并咪唑衍生物及应用
CN108997320A (zh) * 2018-08-30 2018-12-14 深圳市坤健创新药物研究院 一种含氟取代苯并咪唑衍生物及应用
WO2020196712A1 (ja) * 2019-03-27 2020-10-01 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲートとｐａｒｐ阻害剤の組み合わせ
PE20220563A1 (es) 2019-07-10 2022-04-13 Cybrexa 2 Inc Conjugados peptidicos de citotoxinas como terapeuticos
CN114302744A (zh) 2019-07-10 2022-04-08 赛博克萨3公司 作为治疗剂的微管靶向剂的肽缀合物
CN114053415B (zh) * 2020-07-30 2024-06-18 江苏天士力帝益药业有限公司 Tsl-1502复方药物组合
WO2023208341A1 (en) 2022-04-27 2023-11-02 ITM Isotope Technologies Munich SE Combination treatment of small-cell lung cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT841924E (pt) * 1995-08-02 2003-02-28 Univ Newcastle Ventures Ltd Compostos de benzimidazolo
JPH10511108A (ja) * 1995-08-28 1998-10-27 シェーリング コーポレイション テモゾロミドおよびシスプラチンを含む進行ガンに対する組み合わせ治療
AU735801B2 (en) * 1997-07-02 2001-07-12 Atofina Chemicals, Inc. Fluoropolymer dispersion coatings from modified thermoplastic vinylidene fluoride based resins
ATE259789T1 (de) * 1998-11-27 2004-03-15 Abbott Gmbh & Co Kg Substituierte benzimidazole und ihre verwendung als parp inhibitoren
MXPA01007001A (es) * 1999-01-11 2002-07-30 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas.
CN102160864A (zh) * 1999-03-30 2011-08-24 先灵公司 用替莫唑胺改善癌症治疗
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
AU7314200A (en) * 1999-09-17 2001-04-24 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
US7196085B2 (en) * 2002-04-30 2007-03-27 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP2006522088A (ja) * 2003-03-31 2006-09-28 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩
WO2004105700A2 (en) * 2003-05-28 2004-12-09 Guildford Pharmaceuticals, Inc. Compounds, methods and pharmaceutical compositions for inhibiting parp
CN101098696A (zh) * 2004-11-09 2008-01-02 先灵公司 基于患者mgmt水平来治疗癌症的替莫唑胺的改进给药方案
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
CA2612979A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. Parp modulators and treatment of cancer
EP1908481A1 (en) * 2005-06-24 2008-04-09 Ono Pharmaceutical Co., Ltd. Agent for reduction of bleeding in cerebrovascular disorder

Also Published As

Publication number Publication date
US20120045524A1 (en) 2012-02-23
RS53082B (en) 2014-06-30
WO2007084532A3 (en) 2007-09-07
JP2017160216A (ja) 2017-09-14
CA2635691A1 (en) 2007-07-26
CA2635691C (en) 2013-10-29
CN101370497A (zh) 2009-02-18
JP2013136605A (ja) 2013-07-11
EP2338487A1 (en) 2011-06-29
HRP20131180T1 (hr) 2014-01-31
EP2329818A1 (en) 2011-06-08
CN101370497B (zh) 2010-11-17
JP2015187114A (ja) 2015-10-29
US20070265324A1 (en) 2007-11-15
EP1976515A2 (en) 2008-10-08
ME02121B (me) 2014-06-30
US20110152336A1 (en) 2011-06-23
JP2009523801A (ja) 2009-06-25
JP6147799B2 (ja) 2017-06-14
JP5289060B2 (ja) 2013-09-11
SI2338487T1 (sl) 2014-01-31
US20110151023A1 (en) 2011-06-23
WO2007084532A2 (en) 2007-07-26
ES2437132T3 (es) 2014-01-09
EP2338487B1 (en) 2013-09-11
PL2338487T3 (pl) 2014-03-31
PT2338487E (pt) 2013-12-16

Similar Documents

Publication Publication Date Title
DK2338487T3 (da) Kombinationsterapi med PARP-inhibitorer
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
NL300936I2 (nl) Semaglutide
ATE400567T1 (de) Kinaseinhibitoren
DK1926722T3 (da) Substituerede benzimidazoler som kinaseinhibitorer
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
NO20090313L (no) Derivater og analoger av N-etylkinoloner og N-etylazakinoloner
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
NO20083726L (no) Spiroindolinon derivater
GT200900014A (es) Derivados de i-(-d-glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indoly uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio.
ATE540936T1 (de) Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
CY2014012I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
PA8667201A1 (es) Nuevos compuestos farmaceuticos
CY1111628T1 (el) Υποκατεστημενες ενωσεις δικυκλολακταμης
DOP2005000010A (es) Inhibidores de quinasa
ATE553104T1 (de) Substituierte 1h-benzimidazol-4-carboxamide als potente parp-hemmer
RS52255B (en) NALMEFEN HYDROCHLORIDE DIHYDRATE
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
SG149831A1 (en) Benzimidazole derivatives
ATE542800T1 (de) Kinasehemmer und ihre anwendungsverfahren
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
DE112007003237A5 (de) Nachspannendes Bohrfutter